Healthy Mamas: A Weight Maintenance Program Promoting Fat Loss in Pregnancy in Women With Grade 2 and 3 Obesity

Sponsor
Pennington Biomedical Research Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04731688
Collaborator
California Polytechnic State University-San Luis Obispo (Other), Oregon Health and Science University (Other), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
100
2
2
44.7
50
1.1

Study Details

Study Description

Brief Summary

The aims of this randomized controlled trial are to determine the effects of a lifestyle program that supports weight maintenance and fat mass loss during pregnancy in women with grade 2 and 3 obesity on changes in 1) maternal weight, fat mass, and cardiometabolic risk factors; 2) safety measures, including fetal and neonatal growth; 3) the mediators and moderators of the fat mass loss intervention and 4) the effects gestational fat mass loss has on reducing incidence of adverse obstetrical outcomes, including non-elective cesarean delivery, gestational diabetes, hypertension, and pre-eclampsia.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Weight Maintenance Group
N/A

Detailed Description

One hundred pregnant women with grade 2 or 3 obesity who are otherwise healthy will be studied from early pregnancy until approximately 2 weeks postpartum. Major assessments will occur at baseline (13-16 weeks gestation), 27-29 weeks gestation, 35-37 weeks gestation, and approximately 2 weeks postpartum. Safety assessments will be collected every 4 weeks after enrollment. Participants will be equally randomized within site (50 individuals at Pennington Biomedical Research Center and 50 individuals at California Polytechnic University) and obesity grade 2 or 3 to either: Provider Directed Group or Weight Maintenance Group.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Two site randomized controlled trialTwo site randomized controlled trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessments will be conducted by staff members who are masked to the participant's intervention group assignment.
Primary Purpose:
Prevention
Official Title:
A Weight Maintenance Program Promoting Fat Loss in Pregnancy in Women With Grade 2 and 3 Obesity
Actual Study Start Date :
Mar 10, 2021
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Weight Maintenance Group

Individuals in this group will receive all aspects of the Provider Directed Group plus a comprehensive behavioral fat mass loss intervention with food provision. Individuals in this group will be provided foods to eat to support weight maintenance and loss of body fat throughout pregnancy. They will be asked to attend two behavioral counseling sessions at the beginning of the study to help learn the program and set goals. They will return for brief visits with a lifestyle counselor every two weeks until 20 weeks gestation and at least once a month until delivery. Individuals will be provided a scale to help keep track of weight during pregnancy.

Behavioral: Weight Maintenance Group
The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.

No Intervention: Provider Directed Group

Individuals in this group will receive what is standard practice by their prenatal care providers during pregnancy. In addition, individuals in this group will be asked to attend a brief session at the time of randomization to familiarize with the study and what is expected. They will also be provided with materials describing healthy behaviors in pregnancy.

Outcome Measures

Primary Outcome Measures

  1. Body weight change from early pregnancy to end of pregnancy [13-16 weeks gestation and 35-37 weeks gestation]

    Body weight will be measured using a calibrated electrical scale with participants wearing a hospital gown and underwear.

  2. Fat mass change from early pregnancy to end of pregnancy [13-16 weeks gestation and 35-37 weeks gestation]

    Fat mass will be assessed via a 3-compartment model in which fat mass is calculated from body weight, body density measured by the BODPOD, and total body water measured by deuterium dilution.

  3. Total body water change from early pregnancy to end of pregnancy [13-16 weeks gestation and 35-37 weeks gestation]

    Total body water is assessed by deuterium dilution.

  4. Fat-free mass change from early pregnancy to end of pregnancy [13-16 weeks gestation and 35-37 weeks gestation]

    Fat-free mass will be calculated as the subtraction of fat mass from total body weight.

  5. Body weight change from early pregnancy to approximately 2 weeks postpartum [13-16 weeks gestation and approximately 2 weeks postpartum]

    Body weight will be measured using a calibrated electrical scale with participants wearing a hospital gown and underwear.

  6. Fat mass change from early pregnancy to approximately 2 weeks postpartum [13-16 weeks gestation and approximately 2 weeks postpartum]

    Fat mass will be assessed via a 3-compartment model in which fat mass is calculated from body weight, body density measured by the BODPOD, and total body water measured by deuterium dilution.

  7. Total body water change from early pregnancy to approximately 2 weeks postpartum [13-16 weeks gestation and approximately 2 weeks postpartum]

    Total body water is assessed by deuterium dilution.

  8. Fat-free mass change from early pregnancy to approximately 2 weeks postpartum [13-16 weeks gestation and approximately 2 weeks postpartum]

    Fat-free mass will be calculated as the subtraction of fat mass from total body weight.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Are pregnant less than or equal to 15 weeks gestation at screening

  • Have a body mass index between 35.0 and 55.0 inclusive

  • Have a confirmed viable singleton gestation

  • Willing to receive randomization to either group

  • Willing and able to eat the study foods

  • Willing to enroll infant for study measurements after birth

  • Receive clearance from the prenatal care provider for participation

Exclusion Criteria:
  • Smoking, drug, or alcohol use

  • Have a known fetal anomaly

  • Have a non-pregnancy related illness

  • Have pre-existing diabetes

  • Have pre-existing hypertension

  • Have severe anemia

  • Have current mental health issue or eating disorder

  • Short inter-pregnancy interval (<6 months since last pregnancy)

  • Use of assisted reproductive technology

  • Use of medications with known effects on body weight including over the counter medications and supplements for weight loss

  • History of pre-eclampsia, prior small for gestational age infant, bariatric surgery

  • Planning to move out of the area in the next 12 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 California Polytechnic State University San Luis Obispo California United States 93407
2 Pennington Biomedical Research Center Baton Rouge Louisiana United States 70808

Sponsors and Collaborators

  • Pennington Biomedical Research Center
  • California Polytechnic State University-San Luis Obispo
  • Oregon Health and Science University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

  • Principal Investigator: Leanne M Redman, Ph.D., Pennington Biomedical Research Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Leanne Redman, Professor, Pennington Biomedical Research Center
ClinicalTrials.gov Identifier:
NCT04731688
Other Study ID Numbers:
  • PBRC 2019-070
  • 1R01DK124806-01
First Posted:
Feb 1, 2021
Last Update Posted:
Jun 9, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Leanne Redman, Professor, Pennington Biomedical Research Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 9, 2022